Advocacy Update March 31, 2026
IN THIS ISSUE / March 31, 2026
Academy reinforces diagnostic imaging interoperability standards
AADA responds to potential fraud, waste, and abuse regulations
Indoor Tanning
AADA urges FDA to issue new Sunlamp Regulation for minors
The AADA recently asked (PDF) the Food and Drug Administration (FDA) to reconsider its decision of withdrawing a proposed indoor sunlamp regulation and finalize restrictions on youth access.
We also requested a meeting with FDA leadership to identify a path forward to ensure safeguards are implemented that protect patient and public health, including establishing a risk certification requirement for adult users. In its letter, the AADA underscored the robust body of scientific evidence linking sunlamp use to significant health risks, particularly among minors.
AADA News
Update on MultiPlan litigation
The Academy is aware of the MultiPlan federal antitrust lawsuit. Advocacy staff met with the American Medical Association (AMA) Litigation Center to discuss the current status of the MultiPlan proceedings.
In 2024, AMA and the Illinois State Medical Societyfiled the lawsuit alleging that MultiPlan conspired with commercial health insurance companies to unfairly reduce payment for out-of-network services resulting in harm to patients and physicians.
AADA staff cannot provide advice about an individual member’s specific situation with MultiPlan or answer any questions of a legal nature. Physicians who believe they have been harmed by MultiPlan and the insurance companies, can obtain a free case evaluation from one of the attorneys appointed by the court to lead the non-class claims.
Regulatory Advocacy
Academy reinforces diagnostic imaging interoperability standards
The Academy continues to advocate for interoperability by encouraging the Department of Health and Human Services (HHS) to consider dermapathology in their standards.
The AADA s submitted a comment letter (PDF) responding to HHS’s RFI on diagnostic imaging on March 13. The letter highlighted the use of diagnostic imaging by dermatopathologists and the distinct characteristics of dermatologic imaging that warrant specific considerations. The considerations laid out in the letter address electronic standards-based diagnostic image access, exchange, and interoperability of diagnostic imaging systems.
Regulatory Advocacy
AADA responds to potential fraud, waste, and abuse regulations
The AADA addressed (PDF) concerns regarding Molecular Diagnostic Tests (MolDx), use of AI in claims adjudication and network adequacy in CMS’s RFI on comprehensive regulations to uncover suspicious health care (CRUSH). The letter provided feedback on possible regulatory changes that might be included in a potential upcoming CRUSH proposed rule, as well as other programmatic changes that could be implemented to make CMS more effective in addressing fraud in Medicare and Medicare Advantage programs.
AADA News
Dr. Miller attends political event on behalf of SkinPAC
Support congressional dermatology champions through SkinPAC
SkinPAC helps strengthen our relationships on Capitol Hill and reinforces our grassroots and lobbying efforts. Your contribution today will help ensure we have the resources we need to ramp up our fight to reform Medicare physician payment in Congress.
As of March 28, SkinPAC has raised $456,399.24. Contribute online at www.skinpac.org or by texting SkinPAC to 71777.
Email skinpac@aad.org with any questions.
Membership dues money cannot be used for political purposes, so your personal contribution to SkinPAC is critical.
The political purpose of the American Academy of Dermatology Association Political Action Committee ("SkinPAC") is to solicit and receive contributions to be used to make political campaign expenditures to those candidates for elective office, and other federal political committees, who demonstrate understanding and interest in the view and goals of the American Academy of Dermatology Association.
Contributions to SkinPAC are not deductible for federal income tax purposes. Contributions to SkinPAC must be made from your funds and may not be reimbursed. SkinPAC cannot accept contributions from corporate accounts. Any recommended contribution amount is merely a suggestion. All AADA members have the right to contribute more or less or refuse to contribute without reprisal. Federal law prohibits us from accepting contributions from foreign nationals. Federal law requires us to use our best efforts to collect and report the name, physical address, occupation, and name of the employer whose contributions exceed $200 in a calendar year.
